Evidence map›Paper›PMID 16942121›Full record

ArticlePharmacoEconomics2006

Using discrete choice experiments within a cost-benefit analysis framework: some considerations.

Emma McIntosh

Abstract read
PubMed Publisher
In one paragraph

Article in PharmacoEconomics, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Discrete choice experiments of pharmacy services: a systematic review.International journal of clinical pharmacy · 2016
    Pooled it
  3. Pooled it
  4. Is next generation sequencing for the diagnosis of rare diseases worth its cost? A user-based approach to valuation.The European journal of health economics : HEPAC : health economics in prevention and care · 2026
    Article
  5. Review
  6. Article
  7. DoesFrontiers in global women's health · 2023
    Article
  8. Article
  9. Article
  10. Article
  11. Exploring Community-Based Options for Reducing Youth Crime.International journal of environmental research and public health · 2021
    Article
  12. Article
  13. Health-related quality of life in Parkinson's: impact of 'off' time and stated treatment preferences.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2016
    Article
  14. Preferences for a third-trimester ultrasound scan in a low-risk obstetric population: a discrete choice experiment.Health expectations : an international journal of public participation in health care and health policy · 2015
    Article
  15. Article
  16. Article
  17. Eliciting individual preferences for health care: a case study of perinatal care.Health expectations : an international journal of public participation in health care and health policy · 2010
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Emma McIntoshDepartment of Public Health, Health Economics Research Centre, University of Oxford, Oxford, UK. emma.mcintosh@dphpc.ox.ac.uk

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A great advantage of the stated preference discrete choice experiment (SPDCE) approach to economic evaluation methodology is its immense flexibility within applied cost-benefit analyses (CBAs). However, while the use of SPDCEs in healthcare has increased markedly in recent years there has been a distinct lack of equivalent CBAs in healthcare using such SPDCE-derived valuations. This article outlines specific issues and some practical suggestions for consideration relevant to the development of CBAs using SPDCE-derived benefits. The article shows that SPDCE-derived CBA can adopt recent developments in cost-effectiveness methodology including the cost-effectiveness plane, appropriate consideration of uncertainty, the net-benefit framework and probabilistic sensitivity analysis methods, while maintaining the theoretical advantage of the SPDCE approach. The concept of a cost-benefit plane is no different in principle to the cost-effectiveness plane and can be a useful tool for reporting and presenting the results of CBAs.However, there are many challenging issues to address for the advancement of CBA methodology using SPCDEs within healthcare. Particular areas for development include the importance of accounting for uncertainty in SPDCE-derived willingness-to-pay values, the methodology of SPDCEs in clinical trial settings and economic models, measurement issues pertinent to using SPDCEs specifically in healthcare, and the importance of issues such as consideration of the dynamic nature of healthcare and the resulting impact this has on the validity of attribute definitions and context.

Indexed as

Cost-Benefit AnalysisEconomics, PharmaceuticalAdvisory CommitteesHealth ServicesHumans

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.